Submit to JPM Review for JPM Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Advanced Research in Glaucoma: Treatment and Postoperative Approaches"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 5640

Share This Special Issue

Special Issue Editor

Dr. Kazuyuki Hirooka

E-Mail Website
Guest Editor

Department of Ophthalmology and Visual Science, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan
Interests: glaucoma; neuroprotection; aldosterone; MIGS; glaucoma surgery

Special Issue Information

Dear Colleagues,

Treatment goals for glaucoma have focused almost exclusively on lowering intraocular pressure (IOP) using drugs, laser therapy, or surgery. Surgery should be considered whenever medical or laser treatment is unlikely to maintain sight in the glaucomatous eye. This Special Issue of the Journal of Personalized Medicine aims to highlight the current treatment of glaucoma. It is important to investigate both the safety and the efficacy of IOP-lowering medication, laser surgery, or incisional surgery. I am confident that the results of such studies will be beneficial not only for glaucoma patients but also for physicians. The accumulation of these results will improve the quality of life in patients with glaucoma.

Dr. Kazuyuki Hirooka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

medical treatment
adherence
laser surgery
incisional surgery
minimally invasive glaucoma surgery
long-tube glaucoma drainage devices

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Editorial

Jump to: Research

Open AccessEditorial

Advanced Research in Glaucoma: Treatment and Postoperative Approaches

Kazuyuki Hirooka

J. Pers. Med. 2023, 13(6), 895; https://doi.org/10.3390/jpm13060895 - 25 May 2023

Viewed by 489

Abstract

The principal proven treatment methods for glaucoma management almost exclusively focus on lowering the intraocular pressure (IOP) [...] Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

Research

Jump to: Editorial

Open AccessCommunication

“Ab Interno” Surgery of the Schlemm’s Canal in Postuveitic Glaucoma Patients

Ivan Tanev

and

Radina Kirkova

J. Pers. Med. 2023, 13(3), 456; https://doi.org/10.3390/jpm13030456 - 28 Feb 2023

Cited by 1 | Viewed by 687

Abstract

Background: Patients with uveitis have a higher risk of developing glaucoma not only because of the disease by itself, but also because of the ongoing corticosteroid therapy. The pathogenesis of uveitic glaucoma is characterized by a complex of biochemical and cellular processes, as well as morphological changes in the trabecular meshwork. Treatment of secondary chronic glaucoma is challenging and often requires different approaches and solutions. Purpose: To present the “ab interno” procedure of the Schlemm‘s canal (SC) performed with the help of TrabEx+ (MST, Redmond, WA, USA) in postuveitic glaucoma patients. Methods: The observed group included patients with postuveitic secondary glaucoma, which consisted of 12 pseudophakic patients (12 eyes). Patients are with intraocular pressure higher than 25 mmHg and on maximal local therapy. Due to insufficient conservative control on IOP, surgical solutions are needed. We describe a new, minimally invasive surgical procedure–the technique of the operation, the postoperative results and complications. Results: We present the achieved intraocular pressure (on the first day, 2 weeks, 1 month, 6, 8 12 and 18 months). The morphology of the trabecular area was demonstrated by gonioscopy. The effects of the therapy on the glaucoma progression, was evaluated with perimetry and OCT. Discussion: The following procedure is a minimally invasive procedure and provides good control of intraocular pressure. Aqueous veins in the conjunctiva are significantly preserved compared to conventional filtration trabeculectomy. This potentially modulates the physiological outflow pathways by ablating trabeculum strip the cause of increased outflow resistance-the inner wall of the SC. Conclusion: Removal of the inner wall of the SC, using Trabex+ (MST, Redmond, WA, USA), demonstrates promising results in the selected patients with a minimally invasive nature. Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

► Show Figures

Figure 1

Open AccessArticle

Corneal Endothelial Cell Loss after Ciliary Sulcus Placement of Ahmed Glaucoma Valve in Patients with Noninfectious Uveitic Glaucoma

and

J. Pers. Med. 2022, 12(12), 2075; https://doi.org/10.3390/jpm12122075 - 16 Dec 2022

Cited by 1 | Viewed by 928

Abstract

This study was performed to investigate the corneal endothelial cell density (CECD) reduction and treatment efficacy in patients with uveitic glaucoma treated by the ciliary sulcus placement of the Ahmed glaucoma valve (AGV). This retrospective study included 27 eyes of 27 patients with noninfectious uveitis who underwent the sulcus placement of the AGV. Each patient underwent a clinical assessment including a CECD measurement before surgery and at 3, 6, 9, and 12 months after surgery. The mean CECD was 2431.4 ± 367.5 cells/mm² at preoperative baseline and 2360.5 ± 391.3 cells/mm² at 12 months (p = 0.074), with a reduction rate of 2.73 ± 9.29%. The CECD reduction was significantly greater in patients with unilateral uveitis than that with bilateral uveitis. The rate of successful intraocular pressure control was 88% at 12 months, and the number of intraocular pressure-lowering medications was significantly reduced (p < 0.001). The current study showed that the implantation of an Ahmed tube into the ciliary sulcus provided stable intraocular pressure control in patients with glaucoma secondary to noninfectious uveitis, and CECD reduction was moderate in most patients at 12 months. Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

► Show Figures

Figure 1

Open AccessArticle

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients

and

J. Pers. Med. 2022, 12(12), 2057; https://doi.org/10.3390/jpm12122057 - 13 Dec 2022

Cited by 1 | Viewed by 743

Abstract

We evaluated switching from brinzolamide 1% or brimonidine 0.1% to a fixed-combination of brinzolamide 1% and brimonidine 0.1%, and then determined the efficacy, safety, and satisfaction associated with these changes in glaucoma patients. This prospective, nonrandomized study evaluated a total of 31 enrolled glaucoma patients who underwent treatment with at least brinzolamide 1% or brimonidine 0.1%. Patients were administered a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC) after being switched from their original brinzolamide 1% or brimonidine 0.1% therapy. All other intraocular pressure (IOP)-lowering medications currently being used were continued. IOP, superficial punctate keratopathy (SPK), and conjunctival hyperemia data obtained at baseline and then at 4 and 12 weeks were evaluated. To assess the changes in treatment satisfaction, this study utilized the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). There was a significant decrease in the mean baseline IOP from 15.7 ± 4.9 mmHg to 13.6 ± 4.4 (p = 0.001) and 13.5 ± 3.9 mmHg (p = 0.002) at 4 and 12 weeks, respectively. Evaluation of the incidence of conjunctival hyperemia or SPK score showed there were no significant changes noted at any time point. The TSQM-9 score demonstrated there was a significant increase for effectiveness after switching from brinzolamide 1% or brimonidine 0.1% to BBFC. After switching from brinzolamide 1% or brimonidine 0.1% to BBFC, there was a significant decrease in the IOP. Patients were aware of the effectiveness of switching from brinzolamide 1% or brimonidine 0.1% to BBFC. Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

► Show Figures

Figure 1

Open AccessArticle

Real-World Analysis of the Aging Effects on Visual Field Reliability Indices in Central 10-2 Tests

and

J. Pers. Med. 2022, 12(10), 1600; https://doi.org/10.3390/jpm12101600 - 28 Sep 2022

Cited by 1 | Viewed by 816

Abstract

We investigated the influence of aging on the reliability indices of visual field (VF) testing using a large dataset of central 10-2 program tests, including 6674 VF tests, which consisted of 1782 eyes of 1094 Japanese subjects (the mean age ± standard deviation was 66.6 ± 14.1 years). All of the combinations for each parameter, except for the pairs between age and fixation losses (FLs) or false positives (FPs) and between pattern standard deviation (PSD) and FPs, had significant correlations (p < 0.0001). Among the reliability indices, the false negatives (FNs) had the strongest correlation against age (the correlation coefficient was ρ = 0.21). Each reliability index changes differently with aging. The FLs were the highest in the first 10 s and remained constant after 20 s. The FNs remained constant for 60 s and rose steeply after 70 s. The FPs reached their highest value in 10 s and remained constant after 40 s. In mixed-effect regression analyses in 40-year-old or older subjects, older age was significantly associated with higher FNs (p < 0.0001) but not with FLs (p = 0.9014) and FPs (p = 0.9267). Compared to central 30-2 VF testing, central 10-2 VF tests were associated with smaller FLs (p < 0.0001) and FPs (p < 0.0001). In central 10-2 testing, age-related deterioration was seen in FNs but not in FLs and FPs. Choosing the 10-2 program over the 30-2 program can be effective in reducing the FL, especially in older cases with severe VF loss. This study highlighted the relationships between age and each reliability index in central 10-2 VF testing. Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

► Show Figures

Figure 1

Open AccessArticle

Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan

Masaki Tanito

J. Pers. Med. 2022, 12(6), 956; https://doi.org/10.3390/jpm12060956 - 11 Jun 2022

Cited by 3 | Viewed by 1307

Abstract

To report the updated prescription trend of antiglaucoma medications, the dose-based prescription of a glaucoma medication in Japan in the fiscal year 2019 was aggregated by using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open data. Of the 100 most frequently prescribed topical medications for outpatients from out-hospital pharmacies, 32 glaucoma medications were identified. This year, 150.8 million ml of glaucoma medications prescribed accounted for 12.3% of the total prescription dose (1.3 billion ml). The dose was the largest with prostaglandin FP_2α agonist (PGF_2α), followed by the fixed-dose combination (FDC) of β-blocker and carbonic anhydrase inhibitor (β + CAI) and α₂-agonist. Prescription doses peaked at 75–79 years old for all medication classes, except for prostaglandin EP₂ agonist of that peaked 10 years younger age class than other medications. The prescription dose was larger in women (55.3%) than men (44.7%), single medication formulation (71.2%) than FDC (28.8%), and brand-name (85.2%) than generic (14.8%). By multivariate analysis, prescription doses were affected by roles of the sex (p = 0.0066) and brand-name or generic (p = 0.032), but not by single medication formulation or FDC (p = 0.67); age was the most remarkable parameter for the difference in prescription dose (p < 0.0001). Dose-based anti-glaucoma medication prescription was analyzed using the government-provided most recent database on a national scale. The results provide the up-to-date real-world glaucoma medication prescriptions where the country has the highest aging rate in the world. Full article

(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Advanced Research in Glaucoma: Treatment and Postoperative Approaches"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (6 papers)

Editorial

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI